Dublin, June 26, 2025 (GLOBE NEWSWIRE) -- The "Tumor Mice Model Market Size, Share, Trends, Analysis, and Forecast 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges" has been added to ResearchAndMarkets.com's offering.
The Global Tumor Mice Model Market is projected to ascend from a valuation of USD 1.25 billion in 2025 to an anticipated USD 2 billion by 2034, driven by a robust CAGR of 7%
The report provides comprehensive data on global, regional, and key country levels, with a detailed outlook to 2034. It explains segmentation by product type, application, and other parameters, offering insights into short and long-term trends, opportunities, and challenges. Analyzing competitive strategies, technological developments, and ethical considerations gives businesses the strategic advantage to plan effectively.
This market is crucial for preclinical oncology research, allowing scientists to analyze tumor biology, assess anti-cancer drugs, and explore resistance mechanisms in a biologically relevant environment. Key models such as patient-derived xenografts (PDX), syngeneic models, and genetically engineered mouse models (GEMMs) play a pivotal role in replicating the human tumor microenvironment, facilitating advanced research in tumor-immune interactions.
Rising cancer incidence and the demand for personalized medicine underscore the significance of these models in drug development pipelines, from target identification through to safety profiling. These mice models provide high translational value, essential for preclinical validation of novel immunotherapies and combination treatments. North America currently leads the market due to strong research funding and a thriving pharmaceutical pipeline, followed by Europe with its collaborative research and regulatory focus on translational science. The Asia-Pacific region is witnessing rapid growth, particularly in China and Japan, propelled by the expansion of contract research organizations and regional oncology research investments.
Market players are concentrating on expanding their repositories of human tumor samples, enhancing engraftment techniques, and integrating humanized immune systems into mice to improve immuno-oncology studies' accuracy. Challenges remain, including ethical considerations, high development costs, and tumor response variability. Nonetheless, strategic alliances with pharmaceutical companies, advancements in CRISPR gene editing, and AI-driven data analysis are propelling innovation.
Key Takeaways - Tumor Mice Model Market
- Tumor mice models offer crucial in vivo platforms for drug efficacy, toxicity, and resistance studies.
- North America holds a leading position supported by NIH funding and cancer-focused academic research.
- Asia-Pacific is gaining significance due to increasing CRO activities and expanding research infrastructure.
- Humanized mice with engrafted immune systems are transforming immunotherapy and checkpoint inhibitor studies.
- AI and bioinformatics enhance model selection and data interpretation.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 150 |
| Forecast Period | 2025 - 2034 |
| Estimated Market Value (USD) in 2025 | $1.25 Billion |
| Forecasted Market Value (USD) by 2034 | $2.3 Billion |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
Companies Featured
- The Jackson Laboratory
- Charles River Laboratories International, Inc.
- Crown Bioscience Inc. (a JSR Life Sciences Company)
- Envigo (a part of Inotiv)
- Hera BioLabs
- Genoway S.A.
- Taconic Biosciences, Inc.
- Champions Oncology, Inc.
- WuXi AppTec
- Pharmaron, Inc.
- Shanghai Model Organisms Center, Inc.
- Ingenious Targeting Laboratory Inc.
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- GemPharmatech Co., Ltd.
- Cyagen Biosciences Inc.
Market Segmentation
- By Product: Orthotopic Models, Xenograft Models, Genetically Engineered Models
- By Application: Oncology Research, Drug Discovery, Toxicology Testing
- By End User: Pharmaceutical Companies, Research Institutes, Biotechnology Companies
- By Technology: In Vivo Imaging, Genomic Engineering, CRISPR Technology
- By Distribution Channel: Online Sales, Direct Sales, Retail Sales
For more information about this report visit https://www.researchandmarkets.com/r/2pihfl
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
